Biomarin Pharmaceutical Stock Price Prediction
| BMRN Stock | USD 63.45 0.89 1.42% |
Oversold Vs Overbought
34
Oversold | Overbought |
Quarterly Earnings Growth 1.607 | EPS Estimate Next Quarter 0.57 | EPS Estimate Current Year 3.2717 | EPS Estimate Next Year 4.1014 | Wall Street Target Price 98.3859 |
Using Biomarin Pharmaceutical hype-based prediction, you can estimate the value of Biomarin Pharmaceutical from the perspective of Biomarin Pharmaceutical response to recently generated media hype and the effects of current headlines on its competitors.
Biomarin Pharmaceutical Hype to Price Pattern
Investor biases related to Biomarin Pharmaceutical's public news can be used to forecast risks associated with an investment in Biomarin. The trend in average sentiment can be used to explain how an investor holding Biomarin can time the market purely based on public headlines and social activities around Biomarin Pharmaceutical. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Some investors profit by finding stocks that are overvalued or undervalued based on market sentiment. The correlation of Biomarin Pharmaceutical's market sentiment to its price can help taders to make decisions based on the overall investors consensus about Biomarin Pharmaceutical.
The fear of missing out, i.e., FOMO, can cause potential investors in Biomarin Pharmaceutical to buy its stock at a price that has no basis in reality. In that case, they are not buying Biomarin because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Biomarin Pharmaceutical after-hype prediction price | USD 63.35 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Biomarin |
Biomarin Pharmaceutical After-Hype Price Prediction Density Analysis
As far as predicting the price of Biomarin Pharmaceutical at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Biomarin Pharmaceutical or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Biomarin Pharmaceutical, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Biomarin Pharmaceutical Estimiated After-Hype Price Volatility
In the context of predicting Biomarin Pharmaceutical's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Biomarin Pharmaceutical's historical news coverage. Biomarin Pharmaceutical's after-hype downside and upside margins for the prediction period are 60.79 and 65.91, respectively. We have considered Biomarin Pharmaceutical's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Biomarin Pharmaceutical is very steady at this time. Analysis and calculation of next after-hype price of Biomarin Pharmaceutical is based on 3 months time horizon.
Biomarin Pharmaceutical Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Biomarin Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biomarin Pharmaceutical backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Biomarin Pharmaceutical, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.52 | 2.58 | 0.10 | 0.15 | 10 Events / Month | 14 Events / Month | In about 10 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
63.45 | 63.35 | 0.16 |
|
Biomarin Pharmaceutical Hype Timeline
Biomarin Pharmaceutical is currently traded for 63.45. The entity has historical hype elasticity of -0.1, and average elasticity to hype of competition of 0.15. Biomarin is projected to decline in value after the next headline, with the price expected to drop to 63.35. The average volatility of media hype impact on the company price is over 100%. The price decrease on the next news is expected to be -0.16%, whereas the daily expected return is currently at -0.52%. The volatility of related hype on Biomarin Pharmaceutical is about 875.36%, with the expected price after the next announcement by competition of 63.60. About 97.0% of the company shares are held by institutions such as insurance companies. The book value of Biomarin Pharmaceutical was currently reported as 28.41. The company has Price/Earnings To Growth (PEG) ratio of 0.39. Biomarin Pharmaceutical had not issued any dividends in recent years. Given the investment horizon of 90 days the next projected press release will be in about 10 days. Check out Biomarin Pharmaceutical Basic Forecasting Models to cross-verify your projections.Biomarin Pharmaceutical Related Hype Analysis
Having access to credible news sources related to Biomarin Pharmaceutical's direct competition is more important than ever and may enhance your ability to predict Biomarin Pharmaceutical's future price movements. Getting to know how Biomarin Pharmaceutical's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Biomarin Pharmaceutical may potentially react to the hype associated with one of its peers.
Biomarin Pharmaceutical Additional Predictive Modules
Most predictive techniques to examine Biomarin price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Biomarin using various technical indicators. When you analyze Biomarin charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Biomarin Pharmaceutical Predictive Indicators
The successful prediction of Biomarin Pharmaceutical stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Biomarin Pharmaceutical, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Biomarin Pharmaceutical based on analysis of Biomarin Pharmaceutical hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Biomarin Pharmaceutical's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Biomarin Pharmaceutical's related companies. | 2021 | 2022 | 2023 | 2024 (projected) | Days Sales Outstanding | 73.82 | 80.33 | 95.61 | 96.45 | PTB Ratio | 3.78 | 4.17 | 3.66 | 3.99 |
Story Coverage note for Biomarin Pharmaceutical
The number of cover stories for Biomarin Pharmaceutical depends on current market conditions and Biomarin Pharmaceutical's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Biomarin Pharmaceutical is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Biomarin Pharmaceutical's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Biomarin Pharmaceutical Short Properties
Biomarin Pharmaceutical's future price predictability will typically decrease when Biomarin Pharmaceutical's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Biomarin Pharmaceutical often depends not only on the future outlook of the potential Biomarin Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Biomarin Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 191.6 M | |
| Cash And Short Term Investments | 1.1 B |
Check out Biomarin Pharmaceutical Basic Forecasting Models to cross-verify your projections. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.607 | Earnings Share 1.66 | Revenue Per Share 14.529 | Quarterly Revenue Growth 0.283 | Return On Assets 0.03 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.